Partnership evolution includes strategic integration of select Novo Nordisk technologies into Aspect BiosystemsAspect will lead development, manufacturing and commercialisation, and Novo Nordisk will ...
VANCOUVER, British Columbia--(BUSINESS WIRE)--Aspect Biosystems, a biotechnology company pioneering the development of bioprinted tissue therapeutics, today announced that it has received a $72.75 ...
Aspect Biosystems Raises US$115 Million Series B Financing to Advance Bioprinted Tissue Therapeutics
VANCOUVER, British Columbia--(BUSINESS WIRE)--Aspect Biosystems, a biotechnology company pioneering the development of bioprinted tissue therapeutics as a new category in regenerative medicine, today ...
Novo Nordisk and Aspect Biosystems have commenced a new phase in their ongoing partnership focused on curative cellular medicines to treat diabetes. The collaboration, which began in 2023, aims to ...
Partnership will leverage Aspect’s proprietary bioprinting technology and Novo Nordisk’s expertise and technology in stem cell differentiation and cell therapy development and manufacturing. Aspect to ...
Novo Nordisk (NVO) (OTCPK:NONOF) signed a licensing agreement with Canada's Aspect Biosystems to develop bioprinted tissue therapies to replace, repair or supplement biological functions inside the ...
Partnership evolution includes strategic integration of select Novo Nordisk technologies into Aspect Biosystems Aspect will lead development, manufacturing and commercialisation, and Novo Nordisk will ...
Novo Nordisk and Aspect Biosystems have started a new phase in their ongoing partnership focused on curative cellular medicines to treat diabetes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results